Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach. (6th March 2017)

• Record Type: Journal Article
• Authors: Zeng, Liuting; Yang, Kailin
• Is Part Of: Journal of ethnopharmacology. Volume 199(2017)
• Page Start: 68
• Page End: 85
• Publication Date: 2017-03-06
• Subjects: ER estrogen receptor -- PGR progesterone receptor -- HER human epidermal growth factor receptor -- CAM complementary and alternative medicine -- TCM traditional Chinese medicine -- YHD Yanghe Decoction -- OB oral bioavailability -- DL drug-likeness -- PPI protein-protein interaction -- GO Gene Ontology -- IGFR insulin-like growth factor receptor -- HB-EGF heparin-binding growth factor -- EGFR epidermal growth factor receptor -- PRE progesterone response element -- TGF transforming growth factor -- HDAC histone deacetylase -- CDK cyclin dependent kinases -- EMT epithelial-mesenchymal transition -- IGFBP IGF-binding protein -- FGFR fibroblast growth factor receptor; Yanghe Decoction -- HER2-positive breast cancer -- Network pharmacology -- Traditional Chinese medicine -- Chinese medicine formulae; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2017.01.045
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Certain Chinese medicine formulae from traditional Chinese Medicine (TCM) are effective for treating and preventing diseases in clinical practice. Yanghe Decoction (YHD) is a Chinese medicine formula that is used to treat breast cancer, especially HER-positive breast cancer; however, the active compounds, potential targets, and pharmacological and molecular mechanism of its action against cancer remain unclear. Therefore, further investigation is required. Methods: A network pharmacology approach comprising drug-likeness evaluation, oral bioavailability prediction, Caco-2 permeability prediction, multiple compound target prediction, multiple know target collection, breast cancer genes collection, and network analysis has been used in this study. Results: Four networks are set up, including HER2-positive breast cancer network, compound-compound target network of YHD, YHD-HER2-positive breast cancer network and compound-known target-HER2-positive breast cancer network, and some HER2-positive breast cancer and YHD related targets, clusters, biological processes and pathways are found. We also found some potential anti-cancer compounds. Conclusion: Our works successfully predict, illuminate and confirm the molecular synergy of YHD for HER2-positive breast cancer and found the potential HER2-positive breast cancer associated targets, cluster, biological processes and pathways. This study not only provide clues to the researcher who explores pharmacological and molecular mechanism of YHD acting on HER2-positive breast cancer, but also demonstrates a feasible method for discovering potential drugs from Chinese medicine formulae. Graphical abstract: